Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China flag China · Delayed Price · Currency is CNY
11.95
-0.23 (-1.89%)
Sep 10, 2026, 3:04 PM CST

SHE:002900 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-290.67-339.6358.6873.6630.21350.95
Depreciation & Amortization
149.07142.29111.46108.68106.5799.13
Other Amortization
6.186.135.215.353.784.02
Loss (Gain) From Sale of Assets
0.970.52-0.192.6113.311.92
Asset Writedown & Restructuring Costs
10.0631.590-0.822.91-0.69
Loss (Gain) From Sale of Investments
-13.06-10.22-17.78-56.11-59.83-593.2
Provision & Write-off of Bad Debts
-2.62-2.621.22-2.860.591.8
Other Operating Activities
42.6363.1228.651.51-2.3816.1
Change in Accounts Receivable
96.66174.91-135.48-6.74-10.0349.61
Change in Inventory
42.6431.74-98.88-46.80.6226.49
Change in Accounts Payable
-48.11-122.4476.7-51.4247.19-63.69
Operating Cash Flow
-11.51-36.2530.6935.69144.64-12.53
Operating Cash Flow Growth
---14.02%-75.32%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-169.13-247.73-346.21-299.58-89.22-73.95
Sale of Property, Plant & Equipment
0.530.540.030.220.2711.61
Cash Acquisitions
----15.98--
Divestitures
------4.05
Investment in Securities
10-114-6.0846.69500-227.73
Other Investing Activities
20.729.1420.858.128.2115.89
Investing Cash Flow
-137.9-332.04-331.41-260.52419.25-278.23

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-1,058859.55280431471.6
Total Debt Issued
855.381,058859.55280431471.6
Long-Term Debt Repaid
--901.32-643.77-242.47-274.74-282.46
Lease Payments
-2.47-2.47-5.24-7.29-4.53-12.92
Total Debt Repaid
-862.11-901.32-643.77-242.47-274.74-282.46
Net Debt Issued (Repaid)
-6.73156.95215.7737.53156.26189.14
Repurchase of Common Stock
-0.02-0.02-0.22-1.17--
Common Dividends Paid
-29.34-110.28-104.56-41.04-109.34-34.31
Other Financing Activities
2.81208.65202.85-10.41-154.04-198.53
Financing Cash Flow
-33.27255.3313.85-15.08-107.12-43.71

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
-182.68-11313.12-239.91456.77-334.48

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-180.64-283.98-315.52-263.8955.42-86.48
Free Cash Flow Growth
------
Free Cash Flow Margin
-22.44%-35.97%-27.86%-22.23%5.39%-9.14%
Free Cash Flow Per Share
-0.57-0.90-1.02-0.860.18-0.28
Levered Free Cash Flow
-160.44-231.31-366.73-243.0383.23-28.2
Unlevered Free Cash Flow
-143.9-214.77-347.16-228.7297.37-19.57
Free Cash Flow After Leases
-183.11-286.45-320.75-271.1850.89-99.41

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
39.5837.4742.2692.1285.8574.74
Change in Working Capital
85.9372.56-156.54-96.3249.49107.42